Redeye Says Neem’s Hill Underlying Progress Points to Sales Growth
Redeye published a Q3 review of Neem’s Hill, saying underlying progress points to sales growth.
Related stories
Spectur Reports Q1 FY27 Revenue of A$1.47 Million
Q1 FY27 revenue included A$1.22 million in recurring revenue.
M impact | EQUITY | Oct 30, 2026, 12:12 AM UTC
StrategX Elements Raises $911,110.95 in Private Placement
StrategX Elements raised $911,110.95 in an oversubscribed private placement.
M impact | EQUITY | Oct 30, 2026, 12:12 AM UTC
Eli Lilly raises full-year revenue outlook on drug demand
Eli Lilly raised its full-year revenue outlook, citing stronger demand for obesity and diabetes drugs.
M impact | EQUITY | Oct 30, 2026, 12:11 AM UTC
SoftBank Group shares fall 5.7%
M impact | EQUITY | Oct 30, 2026, 12:09 AM UTC
Arthur J. Gallagher Reports Quarterly Results
Arthur J. Gallagher reported results for the quarter ended September 30; the available report provides no figures.
M impact | EQUITY | Oct 30, 2026, 12:09 AM UTC
Bayer Wins Trial in Roundup Cancer Cases
Bayer won a trial involving allegations that Roundup caused cancer in three women.
M impact | EQUITY | Oct 30, 2026, 12:08 AM UTC